1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Muscle Atrophy - Pipeline Review, H1 2015

Muscle Atrophy - Pipeline Review, H1 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 42 pages

Muscle Atrophy - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Muscle Atrophy - Pipeline Review, H1 2015’, provides an overview of the Muscle Atrophy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Muscle Atrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Atrophy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Muscle Atrophy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Muscle Atrophy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Muscle Atrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Muscle Atrophy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Muscle Atrophy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Muscle Atrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Muscle Atrophy - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Muscle Atrophy Overview 6
Therapeutics Development 7
Pipeline Products for Muscle Atrophy - Overview 7
Pipeline Products for Muscle Atrophy - Comparative Analysis 8
Muscle Atrophy - Therapeutics under Development by Companies 9
Muscle Atrophy - Therapeutics under Investigation by Universities/Institutes 10
Muscle Atrophy - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Muscle Atrophy - Products under Development by Companies 13
Muscle Atrophy - Products under Investigation by Universities/Institutes 14
Muscle Atrophy - Companies Involved in Therapeutics Development 15
Acceleron Pharma, Inc. 15
Eli Lilly and Company 16
Fate Therapeutics, Inc. 17
Novartis AG 18
Rigel Pharmaceuticals, Inc. 19
Muscle Atrophy - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ACE-083 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
bimagrumab - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
LY-2495655 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Small Molecule for Muscle Atrophy - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Small Molecule for Muscular Dystrophy and Other Muscle Disorders - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Small Molecule to Inhibit Growth and Differentiation Factor 8 for Atrophy - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Muscle Atrophy - Recent Pipeline Updates 38
Muscle Atrophy - Dormant Projects 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

Number of Products under Development for Muscle Atrophy, H1 2015 7
Number of Products under Development for Muscle Atrophy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Muscle Atrophy - Pipeline by Acceleron Pharma, Inc., H1 2015 15
Muscle Atrophy - Pipeline by Eli Lilly and Company, H1 2015 16
Muscle Atrophy - Pipeline by Fate Therapeutics, Inc., H1 2015 17
Muscle Atrophy - Pipeline by Novartis AG, H1 2015 18
Muscle Atrophy - Pipeline by Rigel Pharmaceuticals, Inc., H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Muscle Atrophy Therapeutics - Recent Pipeline Updates, H1 2015 38
Muscle Atrophy - Dormant Projects, H1 2015 40

List of Figures

Number of Products under Development for Muscle Atrophy, H1 2015 7
Number of Products under Development for Muscle Atrophy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 21
Number of Products by Stage and Top 10 Targets, H1 2015 22
Number of Products by Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Routes of Administration, H1 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 26
Number of Products by Top 10 Molecule Types, H1 2015 27
Number of Products by Stage and Top 10 Molecule Types, H1 2015 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.